The second-generation of EGFR tyrosine kinase inhibitors, such as afatinib and dacomitinib, are effective against EGFR-mutated breast and lung cancer, but ineffective against T790M-mutated cancer (Abourehab et al., 2021). Here, EGFR is linked to lung carcinoma.